title: Harnessing a physiologic mechanism for siRNA delivery with mimetic lipoprotein particles.
abstract: Therapeutics based on RNA interference (RNAi) have emerged as a potential new class of drugs for treating human disease by silencing the target messenger RNA (mRNA), thereby reducing levels of the corresponding pathogenic protein. The major challenge for RNAi therapeutics is the development of safe delivery vehicles for small interfering RNAs (siRNAs). We previously showed that cholesterol-conjugated siRNAs (chol-siRNA) associate with plasma lipoprotein particles and distribute primarily to the liver after systemic administration to mice. We further demonstrated enhancement of silencing by administration of chol-siRNA pre-associated with isolated high-density lipoprotein (HDL) or low-density lipoprotein (LDL). In this study, we investigated mimetic lipoprotein particle prepared from recombinant apolipoprotein A1 (apoA) and apolipoprotein E3 (apoE) as a delivery vehicle for chol-siRNAs. We show that apoE-containing particle (E-lip) is highly effective in functional delivery of chol-siRNA to mouse liver. E-lip delivery was found to be considerably more potent than apoA-containing particle (A-lip). Furthermore, E-lip-mediated delivery was not significantly affected by high endogenous levels of plasma LDL. These results demonstrate that E-lip has substantial potential as delivery vehicles for lipophilic conjugates of siRNAs.
authors: Alnylam Pharmaceuticals, Inc., Cambridge, MA 02142, USA. tnakayama@verizon.net
authors: Tomoko
authors: T
authors: Nakayama
authors: James S
authors: JS
authors: Butler
authors: Alfica
authors: A
authors: Sehgal
authors: Mariano
authors: M
authors: Severgnini
authors: Tim
authors: T
authors: Racie
authors: Jennifer
authors: J
authors: Sharman
authors: Feng
authors: F
authors: Ding
authors: Svetlana Shulga
authors: SS
authors: Morskaya
authors: Joshua
authors: J
authors: Brodsky
authors: Lubomir
authors: L
authors: Tchangov
authors: Verbena
authors: V
authors: Kosovrasti
authors: Mike
authors: M
authors: Meys
authors: Lubomir
authors: L
authors: Nechev
authors: Gang
authors: G
authors: Wang
authors: Chang Geng
authors: CG
authors: Peng
authors: Yupang
authors: Y
authors: Fang
authors: Martin
authors: M
authors: Maier
authors: Kallanthottathil G
authors: KG
authors: Rajeev
authors: Robert
authors: R
authors: Li
authors: Julia
authors: J
authors: Hettinger
authors: Scott
authors: S
authors: Barros
authors: Valerie
authors: V
authors: Clausen
authors: Xuemei
authors: X
authors: Zhang
authors: Qianfan
authors: Q
authors: Wang
authors: Renta
authors: R
authors: Hutabarat
authors: Nikolay V
authors: NV
authors: Dokholyan
authors: Christian
authors: C
authors: Wolfrum
authors: Muthiah
authors: M
authors: Manoharan
authors: Victor
authors: V
authors: Kotelianski
authors: Markus
authors: M
authors: Stoffel
authors: Dinah Wy
authors: DW
authors: Sah
mesh_terms: D000818:Animals; D016632:Apolipoprotein A-I / Q000008:administration & dosage / Q000737:chemistry; D001057:Apolipoproteins E / Q000008:administration & dosage / Q000737:chemistry; D008074:Lipoproteins / Q000008:administration & dosage* / Q000737:chemistry*; D008075:Lipoproteins, HDL / Q000008:administration & dosage / Q000737:chemistry; D008077:Lipoproteins, LDL / Q000008:administration & dosage / Q000737:chemistry; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D034622:RNA Interference / Q000502:physiology; D034741:RNA, Small Interfering / Q000008:administration & dosage* / Q000235:genetics
chemical_list: D016632:Apolipoprotein A-I; D001057:Apolipoproteins E; D008074:Lipoproteins; D008075:Lipoproteins, HDL; D008077:Lipoproteins, LDL; D034741:RNA, Small Interfering